Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2020 17:24 ET | Source: Immutep Limited

Immutep’s TACTI-002 Data to Be Presented at Society for Immunotherapy of Cancer 2020 Annual Meeting

SYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
October 29, 2020 08:45 ET | Source: Immutep Limited

Immutep to Collaborate with LabCorp to Develop Oncology Services and Products

SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is...
October 23, 2020 08:00 ET | Source: Immutep Limited

Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

Investigator-initiated, placebo controlled and randomized Phase II study evaluating eftilagimod alpha (“efti”) in up to 110 COVID-19 patientsImmutep supplies efti to University Hospital Pilsen, Czech...
October 21, 2020 18:45 ET | Source: Immutep Limited

Immutep Activities Report for the First Quarter of Fiscal Year 2021

Encouraging clinical results from TACTI-002 and INSIGHT-004 trials of eftilagimod alphacompleted recruitment for Stage 1 of Part B in TACTI-002 StudyGranted United States patent relating to...
October 21, 2020 08:00 ET | Source: Immutep Limited

Immutep Granted European Patent for IMP761

SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
October 19, 2020 08:00 ET | Source: Immutep Limited

Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
September 17, 2020 20:23 ET | Source: Immutep Limited

Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

Three complete responses (complete disappearance of all lesions) reported: two in 2nd line head and neck squamous cell carcinoma (HNSCC) and one in 1st line non-small cell lung cancer (NSCLC)Five...
September 17, 2020 19:53 ET | Source: Immutep Limited

Immutep Reports Improving Results from INSIGHT-004 Trial

41.7% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab (previously 33%)Encouraging early anti-tumour activity signals in a variety of cancer...
August 31, 2020 08:00 ET | Source: Immutep Limited

Immutep and Monash University Receive Grant Funding for LAG-3 Project

SYDNEY, Australia, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and research...
August 26, 2020 08:00 ET | Source: Immutep Limited

New Data From Immutep’s efti to be Presented at ESMO

SYDNEY, Australia, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...